Scarica l'app Stockscreener
18.05
3.68%
0.64
Dopo l'orario di chiusura:
18.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Travere Therapeutics at Canaccord Genuity: Strategic Insights from Growth Conference - Investing.com Canada
Travere Therapeutics Receives Positive Growth Outlook from Analysts Amid Filspari's Promising Market Potential and Strategic Initiatives - AInvest
Trendlines Converge — Decision Point for Travere Therapeutics Inc.Earnings Performance Report & Entry Point Confirmation Alerts - beatles.ru
Ichimoku Cloud Indicates Uncertainty Around Travere Therapeutics Inc. [Weekly Risk Report]Free Verified Swing Trading Watchlist - 선데이타임즈
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2025 Earnings Call Transcript - MSN
Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics (TVTX) Is Up 8.3% After Revenue Jump and Narrower Losses in Q2 – What's Changed - simplywall.st
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics price target raised to $34 from $32 at Citi - MSN
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Travere Therapeutics Reports Strong Q2 2025 Growth - MSN
Travere Therapeutics price target raised to $32 from $30 at Wedbush - Yahoo Finance
Travere Therapeutics Earnings Call Highlights FILSPARI Success - TipRanks
Travere Therapeutics shares fall 5.16% intraday despite positive earnings report and price target increase. - AInvest
Scotiabank Raises Price Target for Travere Therapeutics (TVTX) t - GuruFocus
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability - simplywall.st
Travere Therapeutics price target raised to $31 from $30 at Scotiabank - TipRanks
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty - Investing.com
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty By Investing.com - Investing.com South Africa
Wedbush Lifts Price Target on Travere Therapeutics to $32 From $30, Keeps Outperform Rating - MarketScreener
TVTX: Wedbush Raises Price Target and Maintains Outperform Ratin - GuruFocus
Travere: Q2 Earnings Snapshot - Huron Daily Tribune
Travere signals accelerating FILSPARI growth and prepares for FSGS launch while advancing REMS modifications - MSN
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts - Investing.com Canada
Travere Therapeutics Reports Second Quarter 2025 Financial Results - BioSpace
Travere Therapeutics: Scaling the Rare Disease Ladder—Can FILSPARI Sustain Its Momentum? - AInvest
Contradictions Unveiled: Travere Therapeutics' 2025Q2 Earnings Call Highlights Regulatory Challenges and Market Dynamics - AInvest
Transcript : Travere Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Travere Therapeutics 2025 Q2 Earnings Strong Performance with 81.9% Net Loss Reduction - AInvest
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Travere Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Travere Therapeutics shares rise as Q2 results top expectations By Investing.com - Investing.com Australia
Travere Therapeutics shares rise as Q2 results top expectations - Investing.com India
Travere Therapeutics Inc Reports Q2 2025 Earnings: EPS Loss of $0.14 Beats Estimates, Revenue Surpasses Expectations at $114.4 Million - GuruFocus
Travere Therapeutics earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Is Travere Therapeutics (NASDAQ:TVTX) Using Too Much Debt? - 富途牛牛
Travere Therapeutics to Participate at Upcoming Investor ConferencesAugust 5, 2025 - BioSpace
Earnings Preview: Travere Therapeutics - 富途牛牛
RBC to announce third quarter results on August 27, 2025 - The Globe and Mail
Trend Dashboard Flags Travere Therapeutics Inc. As Potential Swing TradeExpert Verified Stock Trade Ideas Backed by Data - metal.it
What are the technical indicators suggesting about Travere Therapeutics Inc.Achieve triple-digit returns with smart investing - Jammu Links News
Should I hold or sell Travere Therapeutics Inc. stock in 2025Grow your portfolio with growth-oriented stocks - Jammu Links News
How does Travere Therapeutics Inc. generate profit in a changing economyFree Investment Community - Jammu Links News
When is Travere Therapeutics Inc. stock expected to show significant growthDouble or triple returns - Jammu Links News
How many analysts rate Travere Therapeutics Inc. as a “Buy”Explosive capital gains - Jammu Links News
Is Travere Therapeutics Inc. a good long term investmentUnlock market-leading stock analysis - Jammu Links News
How does Travere Therapeutics Inc. compare to its industry peersExceptional trading performance - Jammu Links News
How strong is Travere Therapeutics Inc. company’s balance sheetPost Market Guidance With High Returns - jammulinksnews.com
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):